CAJ | 학술논문

目的：探讨血管紧张素转换酶抑制剂（angiotension converting enzyme inhibitor，ACEI）达爽和血管紧张素受体拮抗剂（angiotension receptor blocker，ARB）安博维对扩张型心肌病患者内皮功能的影响。方法：采用超声肱动脉内径测量法，对20例正常人和24例扩张型心肌病患者服用达爽或安博维治疗前后肱动脉内径在反应性充血后和含服硝酸甘油后的百分变化率进行比较，分析ACE-I和ARB对扩张型心肌病内皮功能的影响。结果：治疗前扩张型心肌病患者肱动脉内径在反应性充血前后变化较小，但与对照组比较差异均有统计学意义（P<0.01）；而经达爽或安博维治疗后肱动脉内径反应性充血后变化率明显高于治疗前，比较差异均有统计学意义（P<0.05）；而经达爽或安博维治疗的效果比较差异无统计学意义（P>0.05）。结论：ACE-I和ARB均可改善扩张型心肌病的内皮功能，两者在治疗效果上差异不明显。
목적：탐토혈관긴장소전환매억제제（angiotension converting enzyme inhibitor，ACEI）체상화혈관긴장소수체길항제（angiotension receptor blocker，ARB）안박유대확장형심기병환자내피공능적영향。방법：채용초성굉동맥내경측량법，대20례정상인화24례확장형심기병환자복용체상혹안박유치료전후굉동맥내경재반응성충혈후화함복초산감유후적백분변화솔진행비교，분석ACE-I화ARB대확장형심기병내피공능적영향。결과：치료전확장형심기병환자굉동맥내경재반응성충혈전후변화교소，단여대조조비교차이균유통계학의의（P<0.01）；이경체상혹안박유치료후굉동맥내경반응성충혈후변화솔명현고우치료전，비교차이균유통계학의의（P<0.05）；이경체상혹안박유치료적효과비교차이무통계학의의（P>0.05）。결론：ACE-I화ARB균가개선확장형심기병적내피공능，량자재치료효과상차이불명현。
Objective:To evaluate the effects of angiotension converting enzyme inhibitor(ACEI) imidapril or angiotension receptor blocker (ARB)irbesartan on the endothelial function in patients with idiopathic dilated cardiomyopathy by transthoracic echocardiography.Method:Twenty-four patients with idiopathic dilated cardiomyopathy and 20 healthy subjects were included in this study. Brachial artery endothelium dependent dilation function [flow-mediated dilation(FMD)] and nitroglycerin-induced percent changes in the brachial artery diameter were measured by two-dimensional ultrasound before and after the treatment of imidapril or irbesartan and the effect of ACE-I and ARB on endothelial function in dicated cordiomyopathy were analyzed. Result:The treatment of dilated cardiomyopathy patients in the brachial artery diameter had smaller changes before and after the reactive hyperemia,but with the control group had significant difference(P<0.01).The change rate of brachial artery diameter reaction after treatment of imidapril or irbesartan were significantly higher than those before treatment,the differences were statistically significant(P<0.05).But the therapeutic effect of imidapril or irbesartan had no statistically significant difference(P>0.05).Conclusion:ACE-I and ARB can improve the endothelial function in patients with dilated cardiomyopathy,the treatment effect is not obvious difference.